Publicaciones en colaboración con investigadores/as de London School of Hygiene & Tropical Medicine (95)

2024

  1. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

2023

  1. A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2

    Human Mutation, Vol. 2023

  2. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry

    Genome Medicine, Vol. 15, Núm. 1

  3. Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT

    International Journal of Cardiology, Vol. 383, pp. 24-32

  4. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary Interventions

    Journal of the American College of Cardiology, Vol. 82, Núm. 8, pp. 687-700

  5. Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial

    American Journal of Cardiology, Vol. 208, pp. 16-24

  6. Determinants of Progression and Regression of Subclinical Atherosclerosis Over 6 Years

    Journal of the American College of Cardiology, Vol. 82, Núm. 22, pp. 2069-2083

  7. Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention

    JACC: Cardiovascular Interventions, Vol. 16, Núm. 20, pp. 2514-2524

  8. Evaluating the Accuracy of Self-Collected Swabs for the Diagnosis of Mpox

    Clinical Infectious Diseases, Vol. 76, Núm. 7, pp. 1311-1314

  9. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30

  10. Impact of the MEESSI-AHF tool to guide disposition decision-making in patients with acute heart failure in the emergency department: A before-and-after study

    Emergency Medicine Journal, Vol. 41, Núm. 1, pp. 42-50

  11. Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial

    European Heart Journal - Cardiovascular Pharmacotherapy, Vol. 9, Núm. 4, pp. 328-336

  12. Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain

    The Lancet Infectious Diseases, Vol. 23, Núm. 4, pp. 445-453

2022

  1. Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: The SUGAR trial

    European Heart Journal, Vol. 43, Núm. 13, pp. 1320-1330

  2. Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index

    JACC: Cardiovascular Interventions, Vol. 15, Núm. 19, pp. 1948-1960

  3. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study

    The Lancet, Vol. 400, Núm. 10353, pp. 661-669

  4. Common variants in breast cancer risk loci predispose to distinct tumor subtypes

    Breast Cancer Research, Vol. 24, Núm. 1

  5. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial

    The Lancet Diabetes and Endocrinology, Vol. 10, Núm. 1, pp. 35-45

  6. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

    Circulation, Vol. 146, Núm. 20, pp. 1507-1517

  7. Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study

    British Journal of Sports Medicine, Vol. 56, Núm. 20, pp. 1157-1170